PAN3

Summary

PAN3 (poly(A) specific ribonuclease subunit PAN3, HGNC:29991) is a protein-coding gene on chromosome 13q12.2, encoding PAN2-PAN3 deadenylation complex subunit PAN3 (Q58A45). Regulatory subunit of the poly(A)-nuclease (PAN) deadenylation complex, one of two cytoplasmic mRNA deadenylases involved in general and miRNA-mediated mRNA turnover.

Contributes to poly(A)-specific ribonuclease activity. Predicted to be involved in nuclear-transcribed mRNA poly(A) tail shortening. Predicted to act upstream of or within deadenylation-dependent decapping of nuclear-transcribed mRNA; positive regulation of cytoplasmic mRNA processing body assembly; and protein targeting. Part of PAN complex.

Source: NCBI Gene 255967 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 99 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_175854

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29991
Approved symbol	PAN3
Name	poly(A) specific ribonuclease subunit PAN3
Location	13q12.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000152520
Ensembl biotype	protein_coding
OMIM	617448
Entrez	255967

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000380958, ENST00000399613, ENST00000483842, ENST00000503791, ENST00000913194

RefSeq mRNA: 1 — MANE Select: NM_175854 NM_175854

CCDS: CCDS9329

Canonical transcript exons

ENST00000380958 — 19 exons

Exon	Start	End
ENSE00001596848	28281315	28281379
ENSE00001634603	28287984	28288122
ENSE00001645320	28280412	28280541
ENSE00001765480	28271981	28272071
ENSE00001767077	28292382	28295335
ENSE00001785723	28277237	28277376
ENSE00003464717	28261401	28261458
ENSE00003470008	28267300	28267401
ENSE00003486277	28174272	28174393
ENSE00003491918	28220231	28220378
ENSE00003543397	28260447	28260551
ENSE00003546875	28176493	28176559
ENSE00003555811	28197185	28197346
ENSE00003572843	28138545	28139087
ENSE00003587244	28270701	28270866
ENSE00003602204	28177865	28177935
ENSE00003648350	28267095	28267211
ENSE00003655221	28256292	28256539
ENSE00003673271	28266715	28266876

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.3087 / max 375.8485, expressed in 1805 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134552	12.3846	1750
134558	5.7402	1639
134559	1.7566	765
134560	1.3334	895
134557	0.2625	117
134556	0.2581	116
134553	0.1994	80
134570	0.1722	63
134555	0.1157	42
134554	0.0508	14

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.65	gold quality
oviduct epithelium	UBERON:0004804	99.17	gold quality
secondary oocyte	CL:0000655	99.05	gold quality
epithelial cell of pancreas	CL:0000083	98.58	gold quality
thymus	UBERON:0002370	98.33	gold quality
oocyte	CL:0000023	98.20	gold quality
trabecular bone tissue	UBERON:0002483	97.33	gold quality
epithelium of nasopharynx	UBERON:0001951	97.21	gold quality
cerebellar vermis	UBERON:0004720	97.16	gold quality
upper arm skin	UBERON:0004263	97.15	gold quality
ileal mucosa	UBERON:0000331	96.97	gold quality
germinal epithelium of ovary	UBERON:0001304	96.97	gold quality
corpus epididymis	UBERON:0004359	96.76	gold quality
parietal pleura	UBERON:0002400	96.73	gold quality
upper leg skin	UBERON:0004262	96.59	gold quality
seminal vesicle	UBERON:0000998	96.37	gold quality
caput epididymis	UBERON:0004358	96.33	gold quality
nasal cavity epithelium	UBERON:0005384	96.24	gold quality
sperm	CL:0000019	96.18	gold quality
visceral pleura	UBERON:0002401	95.98	gold quality
skin of hip	UBERON:0001554	95.94	gold quality
epithelium of mammary gland	UBERON:0003244	95.94	gold quality
mammary duct	UBERON:0001765	95.93	gold quality
endothelial cell	CL:0000115	95.92	gold quality
layer of synovial tissue	UBERON:0007616	95.84	gold quality
pylorus	UBERON:0001166	95.55	gold quality
esophagus squamous epithelium	UBERON:0006920	95.39	gold quality
cauda epididymis	UBERON:0004360	95.27	gold quality
palpebral conjunctiva	UBERON:0001812	95.21	gold quality
amniotic fluid	UBERON:0000173	95.13	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6819	yes	9983.23
E-MTAB-9801	no	3.79
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

321 targeting PAN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4482-3P	99.98	72.50	3147

Literature-anchored findings (GeneRIF, showing 4)

• hPan2 and hPan3 have roles in mRNA decay and exhibit cytoplasmic co-localization (PMID:14583602)
• arsenite-induced oxidative stress inhibits deadenylation of mRNA primarily through downregulation of Tob and Pan3, both of which mediate the recruitment of deadenylases to mRNA (PMID:25446091)
• These results reveal a new fundamental step governing mammalian mRNA metabolism. We propose that the first phase of deadenylation, coordinated through the interplay among the two Pan3 isoforms, Pan2, and PABP, represents a cytoplasmic mRNA maturation step important for proper mRNA turnover. (PMID:28559491)
• the present study revealed that circPAN3 is most likely a key modulator for acquired drug resistance of AML, which may facilitate drug resistance in AML cells by regulating autophagy as an autophagy inducer via the AMPK/mTOR pathway. (PMID:31401408)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pan3	ENSDARG00000031637
mus_musculus	Pan3	ENSMUSG00000029647
rattus_norvegicus	Pan3	ENSRNOG00000000942
drosophila_melanogaster	PAN3	FBGN0035397
caenorhabditis_elegans		WBGENE00014015

Protein

Protein identifiers

PAN2-PAN3 deadenylation complex subunit PAN3 — Q58A45 (reviewed: Q58A45)

Alternative names: PAB1P-dependent poly(A)-specific ribonuclease, Poly(A)-nuclease deadenylation complex subunit 3

All UniProt accessions (2): Q58A45, A0A0C4DFZ9

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory subunit of the poly(A)-nuclease (PAN) deadenylation complex, one of two cytoplasmic mRNA deadenylases involved in general and miRNA-mediated mRNA turnover. PAN specifically shortens poly(A) tails of RNA and the activity is stimulated by poly(A)-binding protein (PABP). PAN deadenylation is followed by rapid degradation of the shortened mRNA tails by the CCR4-NOT complex. Deadenylated mRNAs are then degraded by two alternative mechanisms, namely exosome-mediated 3’-5’ exonucleolytic degradation, or deadenylation-dependent mRNA decapping and subsequent 5’-3’ exonucleolytic degradation by XRN1. PAN3 acts as a regulator for PAN activity, recruiting the catalytic subunit PAN2 to mRNA via its interaction with RNA and PABP, and to miRNA targets via its interaction with GW182 family proteins. Decreases PAN2-mediated deadenylation, possibly by preventing progression into the second CCR4-NOT mediated stage of biphasic deadenylation. Has a significant effect on mRNA stability, generally stabilizing a subset of the transcriptome. Stabilizes mRNAs degraded by the AU-rich element (ARE)-mediated mRNA decay pathway but promotes degradation of mRNAs by the microRNA-mediated pathway. Its activity influences mRNP remodeling, specifically reducing formation of a subset of P-bodies containing GW220, an isoform of TNRC6A. Enhances PAN2 deadenylase activity and has an extensive effect on mRNA stability, generally enhancing mRNA decay across the transcriptome by multiple pathways, including the AU-rich element (ARE)-mediated pathway, microRNA-mediated pathway and the nonsense-mediated pathway (NMD). Its activity is required for efficient P-body formation. May be involved in regulating mRNAs of genes involved in cell cycle progression and cell proliferation.

Subunit / interactions. Homodimer. Forms a heterotrimer with a catalytic subunit PAN2 to form the poly(A)-nuclease (PAN) deadenylation complex. Interacts (via PAM-2 motif) with poly(A)-binding protein PABPC1 (via PABC domain), conferring substrate specificity of the enzyme complex. Interacts with the GW182 family proteins TNRC6A, TNRC6B and TNRC6. Interacts with YTHDF3. Interacts with HELZ. Interacts with PAN2. Interacts (via N-terminus) with PABPC1 at lower efficiency than isoform 3. Interacts with PAN2. Interacts (via N-terminus) with PABPC1 at higher efficiency than isoform 1.

Subcellular location. Cytoplasm. P-body Cytoplasm. Nucleus Cytoplasm.

Domain organisation. The N-terminal zinc finger binds to poly(A) RNA. Contains a pseudokinase domain. The protein kinase domain is predicted to be catalytically inactive because some of the residues important for catalytic activity are substituted and it lacks the equivalent of the binding site for a peptide substrate. However, it has retained an ATP-binding site and ATP-binding is required for mRNA degradation, stimulating the activity of the PAN2 nuclease in vitro. The nucleotide-binding site is juxtaposed to the RNase active site of PAN2 in the complex and may actually bind nucleosides of a poly(A) RNA rather than ATP, feeding the poly(A)-tail to the active site of the deadenylase and thus increasing the efficiency with which this distributive enzyme degrades oligo(A) RNAs. The pseudokinase domain, the coiled-coil (CC), and C-terminal knob domain (CK) form a structural unit (PKC) that forms an extensive high-affinity interaction surface for PAN2.

Similarity. Belongs to the protein kinase superfamily. PAN3 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q58A45-1	1, Pan3b, Pan3L	yes
Q58A45-2	2
Q58A45-3	3, Pan3S
Q58A45-4	4

RefSeq proteins (1): NP_787050* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000571	Znf_CCCH	Domain
IPR000719	Prot_kinase_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR030844	PAN3	Family
IPR036855	Znf_CCCH_sf	Homologous_superfamily
IPR041332	Pan3_CK	Domain

Pfam: PF18101

UniProt features (29 total): region of interest 6, splice variant 5, sequence conflict 4, compositionally biased region 3, binding site 3, modified residue 2, mutagenesis site 2, chain 1, zinc finger region 1, coiled-coil region 1, short sequence motif 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9QTU	ELECTRON MICROSCOPY	4.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q58A45-F1	64.34	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 521; 570–577; 644–645

Post-translational modifications (2): 354, 361

Mutagenesis-validated functional residues (2):

Position	Phenotype
203	reduces interaction with polyadenylate-binding protein.
293	reduces interaction with polyadenylate-binding protein.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-429947	Deadenylation of mRNA

MSigDB gene sets: 269 (showing top): GOMF_RNA_NUCLEASE_ACTIVITY, GOBP_P_BODY_ASSEMBLY, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOMF_NUCLEASE_ACTIVITY, GOBP_PROTEIN_TARGETING, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GCAAGGA_MIR502, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GTGCCTT_MIR506, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, REACTOME_DEADENYLATION_OF_MRNA

GO Biological Process (7): nuclear-transcribed mRNA poly(A) tail shortening (GO:0000289), deadenylation-dependent decapping of nuclear-transcribed mRNA (GO:0000290), mRNA processing (GO:0006397), protein targeting (GO:0006605), positive regulation of cytoplasmic mRNA processing body assembly (GO:0010606), nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:0000288), protein phosphorylation (GO:0006468)

GO Molecular Function (9): protein kinase activity (GO:0004672), ATP binding (GO:0005524), poly(A) binding (GO:0008143), zinc ion binding (GO:0008270), nucleotide binding (GO:0000166), RNA binding (GO:0003723), poly(A)-specific ribonuclease activity (GO:0004535), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): P-body (GO:0000932), nucleus (GO:0005634), cytosol (GO:0005829), PAN complex (GO:0031251), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Deadenylation-dependent mRNA decay	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear-transcribed mRNA catabolic process	3
nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay	2
cytoplasm	2
cellular anatomical structure	2
mRNA methylguanosine-cap decapping	1
RNA processing	1
mRNA metabolic process	1
establishment of protein localization	1
regulation of cytoplasmic mRNA processing body assembly	1
P-body assembly	1
positive regulation of organelle assembly	1
mRNA destabilization	1
phosphorylation	1
protein modification process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
poly-purine tract binding	1
transition metal ion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
nucleic acid binding	1
3’-5’-RNA exonuclease activity	1
binding	1
cation binding	1
cytoplasmic ribonucleoprotein granule	1
intracellular membrane-bounded organelle	1
exoribonuclease complex	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

671 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PAN3	STKLD1	Q8NE28	517
PAN3	PSKH2	Q96QS6	510
PAN3	PEAK3	Q6ZS72	491
PAN3	FAM20A	Q96MK3	488
PAN3	PGGT1B	P53609	455
PAN3	SELENOO	Q9BVL4	410
PAN3	PEAK1	Q9H792	410
PAN3	BTBD1	Q9H0C5	397
PAN3	PABPC1	P11940	396
PAN3	OTUD7A	Q8TE49	389
PAN3	RIBC2	Q9H4K1	372
PAN3	KSR1	Q8IVT5	371
PAN3	NACC2	Q96BF6	359
PAN3	PAN2	Q504Q3	353
PAN3	XRN1	Q8IZH2	352

IntAct

50 interactions, top by confidence:

A	B	Type	Score
NHERF2	PODXL	psi-mi:“MI:0914”(association)	0.770
PAN3	PAN2	psi-mi:“MI:0915”(physical association)	0.740
PAN2	PAN3	psi-mi:“MI:0915”(physical association)	0.740
PAN3	PAN2	psi-mi:“MI:0403”(colocalization)	0.740
PAN3	PABPC1	psi-mi:“MI:0914”(association)	0.700
PABPC1	PAN3	psi-mi:“MI:0915”(physical association)	0.700
PAN3	PABPC1	psi-mi:“MI:0407”(direct interaction)	0.700
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.640
ASF1A	HAT1	psi-mi:“MI:0914”(association)	0.640
PAN3	TNRC6B	psi-mi:“MI:0915”(physical association)	0.630
TNRC6B	PAN3	psi-mi:“MI:0407”(direct interaction)	0.630
TNRC6B	PAN3	psi-mi:“MI:0915”(physical association)	0.630
TNRC6C	CNOT1	psi-mi:“MI:0914”(association)	0.620
TNRC6B	CNOT1	psi-mi:“MI:0914”(association)	0.580
ASF1A	MCM4	psi-mi:“MI:0914”(association)	0.530
CLEC11A	VWA8	psi-mi:“MI:0914”(association)	0.530
TNRC6C	PAN2	psi-mi:“MI:0914”(association)	0.530
TNRC6C	PAN3	psi-mi:“MI:0915”(physical association)	0.500
PAN3	TNRC6A	psi-mi:“MI:0915”(physical association)	0.500
PAN3	TNRC6C	psi-mi:“MI:0915”(physical association)	0.500
TNRC6A	CNOT1	psi-mi:“MI:0914”(association)	0.500
PAN2	PAN3	psi-mi:“MI:0915”(physical association)	0.400
PAN3	SVIL	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.350
PAN2	ARCN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (94): PAN3 (Affinity Capture-Western), PABPC1 (Affinity Capture-Western), PAN3 (Affinity Capture-Western), PAN3 (Affinity Capture-Western), PAN3 (Affinity Capture-Western), TNRC6C (Affinity Capture-Western), PAN3 (Reconstituted Complex), PAN3 (Co-fractionation), PAN3 (Affinity Capture-MS), PAN3 (Affinity Capture-MS), PAN3 (Affinity Capture-MS), KIAA0430 (Affinity Capture-MS), PAN3 (Affinity Capture-MS), PAN3 (Affinity Capture-RNA), PAN3 (Affinity Capture-Western)

ESM2 similar proteins: A0A1W2P872, A1L1C7, A4IIM2, B2RYD2, F1LQ48, O57406, O88532, O95319, P14866, P28659, P51513, P57723, P57724, Q28HE9, Q2PFW9, Q32PX7, Q3U0V1, Q3US41, Q4QQT3, Q4R535, Q58A45, Q5F3T7, Q5NVC8, Q5R8Y8, Q5R995, Q5U231, Q640Q5, Q6DGV1, Q6GPM1, Q6NXG1, Q6P0B1, Q6PF35, Q792H5, Q7T2T1, Q7TSY6, Q7ZXE2, Q80WA4, Q8R081, Q8UVD9, Q91WJ8

Diamond homologs: A1CP31, A1D1Y5, A1L1C7, A2QAQ3, A3LQL9, A5DCP8, A5E2Y4, G0S0Y3, P0CD65, P0CP50, P0CP51, P34653, P36102, Q0D0A1, Q0V0I4, Q1E2S2, Q2H401, Q2KFH6, Q2U0M4, Q58A45, Q5AK10, Q5BFB1, Q640Q5, Q6BRV5, Q6CBZ0, Q6CP23, Q6FKP2, Q6MY57, Q75BU9, Q7SDP4, Q95RR8, Q9UST1, O13865, P38070

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PAN3	“form complex”	“PAN2-PAN3 deadenylation complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 43 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TP53 Regulates Metabolic Genes	7	37.9×	5e-08
G2/M Checkpoints	5	28.0×	8e-06
Cell Cycle Checkpoints	5	18.4×	4e-05
Cell Cycle	5	7.5×	1e-03
Signaling by Rho GTPases	5	7.1×	2e-03
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	5	7.0×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay	5	156.0×	1e-08

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	68
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1209857	GRCh37/hg19 13q12.2-12.3(chr13:28669064-31367407)x1	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

5789 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:28138802:T:A	C49S	1.000
13:28138802:T:C	C49R	1.000
13:28138803:G:A	C49Y	1.000
13:28138803:G:C	C49S	1.000
13:28138804:C:G	C49W	1.000
13:28138829:T:A	C58S	1.000
13:28138829:T:C	C58R	1.000
13:28138830:G:A	C58Y	1.000
13:28138830:G:C	C58S	1.000
13:28138831:C:G	C58W	1.000
13:28138847:T:A	C64S	1.000
13:28138847:T:C	C64R	1.000
13:28138848:G:C	C64S	1.000
13:28138849:T:G	C64W	1.000
13:28138853:T:C	F66L	1.000
13:28138855:C:A	F66L	1.000
13:28138855:C:G	F66L	1.000
13:28256498:T:C	Y403H	1.000
13:28256498:T:G	Y403D	1.000
13:28256501:T:C	F404L	1.000
13:28256503:C:A	F404L	1.000
13:28256503:C:G	F404L	1.000
13:28260547:G:C	R450P	1.000
13:28261405:T:C	L453P	1.000
13:28266738:T:G	Y479D	1.000
13:28266827:A:C	K508N	1.000
13:28266827:A:T	K508N	1.000
13:28266828:G:C	A509P	1.000
13:28266862:T:A	L520H	1.000
13:28266862:T:C	L520P	1.000

dbSNP variants (sampled 300 via entrez): RS1000002316 (13:28169209 T>A), RS1000016158 (13:28254074 C>T), RS1000022367 (13:28275295 A>T), RS1000023522 (13:28238085 G>A), RS1000030646 (13:28242045 C>T), RS1000077781 (13:28274763 T>C), RS1000082928 (13:28221686 C>T), RS1000095490 (13:28153725 C>T), RS1000120835 (13:28245538 C>T), RS1000131816 (13:28281908 C>G,T), RS1000139120 (13:28221136 G>A), RS1000159488 (13:28162956 T>G), RS1000171550 (13:28142794 T>A), RS1000179481 (13:28292158 C>T), RS1000182732 (13:28206510 T>C,G)

Disease associations

OMIM: gene MIM:617448 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105985 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, decreases expression	2
Valproic Acid	decreases expression, affects expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
arsenite	increases degradation	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
jinfukang	decreases expression	1
Irinotecan	decreases expression	1
Sunitinib	increases expression	1
Caffeine	decreases phosphorylation	1
Diazinon	increases methylation	1
Hydrogen Peroxide	affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1
Ozone	affects expression, increases abundance	1
Theophylline	affects cotreatment, increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1
Magnetite Nanoparticles	decreases methylation	1

ChEMBL screening assays

22 unique, capped per target: 22 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4034444	Binding	Inhibition of PAN3 ATP binding site (unknown origin) at 10 uM	Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus. — Bioorg Med Chem Lett

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5KL	HAP1 PAN3 (-) 2	Cancer cell line	Male
CVCL_XR32	HAP1 PAN3 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.